Calling All Community Oncology and Hematology Clinicians – Don’t Miss This Exciting New Opportunity

Multiple Myeloma ECHO® will run virtually from September 2025 through April 2026

August 14, 2025

AAPA, in partnership with the Boston University Chobanian & Avedisian School of Medicine, Med-IQ, HealthTree Foundation, and the Association of PAs in Oncology, is proud to announce a new and exciting learning opportunity. Beginning in September 2025, interested community oncology clinics can participate in Multiple Myeloma ECHO®, an interactive program designed specifically for community oncology and hematology clinicians, including physician associates and nurse practitioners (NPs).

Multiple myeloma presents ongoing challenges for community oncology practices, with high relapse rates and a disproportionate impact on patients with African ancestry. Although novel B-cell maturation antigen (BCMA) bispecific antibodies (bsAbs) offer significant promise, many clinicians encounter gaps in guideline familiarity, adverse event management, and access to coordinated care.

“PAs and NPs are integral component of the healthcare teams for myeloma patients. Their exemplary care providing education and monitoring adverse effects not only improves the treatment adherence but also the longevity and quality of life,” said Ajay K. Nooka, MD, one of the experts leading Multiple Myeloma ECHO®. “This care is more essential while myeloma patients received bispecific antibodies as timely intervention is of essence for few associated complications.”

[For more information on the program and session dates, visit visit MED-IQ]

Empower your practice and optimize patient outcomes.
This interactive, case-based CME/CE series, led by experts Ajay K. Nooka, MD, of Emory University, and Raphael E. Szalat, MD, of Boston University, is specifically designed for community oncology teams. By participating, your practice will:

• Engage with a multidisciplinary and interprofessional team of expert faculty and other community oncology practices in live Project ECHO® sessions

• Participate in interactive Community of Practice Q&A sessions, fostering direct engagement and knowledge exchange

• Access invaluable clinician and patient toolkits, providing practical resources at your fingertips

• Gain additional resources to support your practice in implementing best practices for BCMA bispecific antibodies

• Translate cutting-edge knowledge into actionable strategies for your patients

Participants should be prepared to share, engage, and fully participate in this “all teach, all learn” environment. A continuous loop of learning, mentoring, and peer support  makes Project ECHO® unique, with a long-lasting impact far beyond that of an in-person training, webinar, or e-learning course.

Why should you join?
Through real patient case discussions, mentorship from a team of multiple myeloma experts, and brief didactic sessions, you’ll gain actionable insights you can apply in your clinic. Participants will:

• Receive a $2,000 stipend for their practice
• Gain deeper understanding of real cases through participant-led discussions
• Get personalized guidance and valuable take-home resources
• Belong to a supportive faculty-led community and enhance your network
• Earn CME, free

Multiple Myeloma ECHO® kicks off September 11th, 2025, and continues with virtual monthly sessions through April 2026.

All clinicians from participating clinics are welcome: Oncologists, hematologists, PAs, NPs, pharmacists, patient navigators, and other healthcare professionals responsible for the care and treatment of people with relapsed/refractory multiple myeloma (RRMM).​

Interested individuals can receive more information or sign up by emailing AAPA’s Sr. Director of Education & Quality, Eric Peterson, at [email protected].

Grantor Acknowledgement:This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

You May Also Like
Top 10 Highest Paying Specialties in the PA Profession in 2024
AAPA Urges Continued Coverage of COVID-19 Vaccine During Pregnancy
Common Questions About Treating Patients with Dementia Experiencing Neuropsychiatric Symptoms